• News
  • Contact
  • Login
Everyone Deserves to Be Well


Atlantic Research Group assumed responsibility for the pivotal Phase III clinical trial for Chelsea Therapeutics' Northera (droxidopa), and provided outstanding leadership and execution for study activities. On February 19, 2014 the U.S. Food and Drug Administration announced it had granted accellerated approval of the drug for use in treating Neurogenic orthostatic hypotension (NOH) a rare, chronic condition characterized by a sudden drop in blood pressure when a person stands.

Read more about ARG's outstanding results for this trial.

ARG's expertise in CNS/Neurology covers all phases, and includes but is not limited to the following indications:

Neurogenic Orthostatic Hypotension Retrospective Studies Patient Reported Outcome Studies Geriatric Care Parkinson's Disease Freezing of Gait